1 / 59

Pulmonary hypertension in LV dysfunction

Pulmonary hypertension in LV dysfunction . Dr Angela Worthington April 5 th 2011. Overview. Normal pulmonary physiology Pathophysiology Clinical research Therapeutic trials. The Right Ventricle. RV is thin walled and distensible

nasnan
Télécharger la présentation

Pulmonary hypertension in LV dysfunction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary hypertension in LV dysfunction Dr Angela Worthington April 5th 2011

  2. Overview • Normal pulmonary physiology • Pathophysiology • Clinical research • Therapeutic trials

  3. The Right Ventricle • RV is thin walled and distensible • Significant component of ejection function comes from bellows effect conferred by negative and positive intra-thoracic pressure. • Normal RV can generate systolic pressures up to 45-50mmHg • Hypertrophied RV can generate higher pressures

  4. Pulmonary circulation Low pressure, high capacity system. Same volume as systemic circulation Normal pulmonary pressure <25mmHg Normal PVR is 67+/-30 dynes Less than 10% of SVR Main determinant of RV afterload and output Even small rises if PAP can result in RV dysfunction

  5. Figure 1. A: transverse section of a pulmonary capillary endothelial cell. At the level of the alveolar capillary unit, processing of vasoactive substances is likely to be maximal. Cells are extremely thin but present a vast surface area that is further enhanced by caveolae and surface projections. B: immunocytochemical localization of angiotensin-converting enzyme on plasma membrane of a pulmonary endothelial cell in culture including caveolae (arrow) and projection (*). The endothelial surface is not only extensive but contains specific enzymes accessible to circulating substrates. C: vasoactive peptides are not only inactivated during circulation through the lungs but also exert effects on pulmonary vascular tone. The mechanism is not fully understood; however, some pulmonary vessels, in this case a small pulmonary artery ~200 um in diameter, exhibit structural interactions known as myoendothelial junctions (*) between endothelial and smooth muscle layers.

  6. Function of pulmonary endothelium

  7. Normal control of pulmonary vasculature

  8. PHT is a predictor of mortality in systolic HF • Abramson, 1992 • 108 pts, all CCF • Mean EF 17% • Echocardiographic • TR velocity • Ventricular indices • FU of 28 months N= 80 N= 28 Abramson et al, Annals of Int Med,1992;116:88-995

  9. Mortality study in HFpEF • Lam et al, JACC 2009; 53: 1119-26 • Echocardiographic derived PASP and PCWP • 719 patients with HT as control • 244 patients with HFpEF • FU 3 years

  10. PASP predicts mortality in HFpEF Lam et al, JACC 2009; 53: 1119-26

  11. PHT and Exercise performance • EF correlates poorly with exercise capacity in HF • Butler et al, JACC 1999; 34 (6): 1802 – 06 • 320 patients for Tx workup

  12. Butler et al. JACC 1999 ; 34, No. 6, :1802–6

  13. Two types of PHT • Pulmonary arterial hypertension (PAH) • Group 1 WHO classification • Pulmonary venous hypertension (PVH) • Group 2 WHO classification Conceptually seen as • Pre-capillary • Post-capillary Dadfarmay et al Congestive Heart Failure, 2010; 16:287 -291

  14. Post Capillary PHT • Consequence of • LV dysfx • diastolic > systolic • Mitral valve disease • Decreased relaxation and compliance of LV • Elevated LV filling pressures • Transmitted back to pulmonary capillaries • Normally remediable to vasodilators

  15. Definition PVH • mPAP > 25mmHg • PCWP > 15 • Transpulmonary gradient (mPAP – PCWP) <10mmHg • Two different haemodynamic phenotypes

  16. 1st phenotype of PVH • Passive retrograde transmission of elevated PCWP into pulmonary venous system • Mild increase in upstream PAP • PAP increases only enough to overcome PCWP to maintain forward flow • TPG remains <10mmHg • In contrast to PAH, where TPG >10mmHg • PHT resolves with treatment of LV dysfx

  17. 1st phenotype Rich and Rabinovitch Circulation 2008;118;2190-2199

  18. 2nd phenotype of PVH • Reactive changes in pulmonary vasculature out of context of raised PCWP • Smooth muscle and vaso-proliferative changes in the pulmonary arterioles • Obliterative arteriopathy mediated by endothelin • TPG >10mmHg • PCWP >15mmHg • PAP does not normalise with Rx of LV dysfx

  19. 2nd phenotype Rich and Rabinovitch Circulation 2008;118;2190-2199

  20. Reactive PVH • More strongly associated with diastolic dysfunction than systolic dysfunction • Prospective echo study Enriquez-Sarano et al 1997 • 102 consecutive patients with CCF and EF < 50% • Strongest correlation with PHT were • Mitral deceleration time < 150msec (OR 48.8) • Mitral ERO >20mm2 (OR 5.9) • No correlation with • EF% • LVESV

  21. Enriques-Sarano et al, JACC 1997;29:153–9

  22. Vascular hypertrophy • Delgado et al, EJHF 2005; 7: 1011–1016 • Study of 17 HT recipients with preoperative CHF who died shortly ( 2.01+/- 2.0 m ) post HTx. • Haemodynamic data were correlated with the morphologic changes seen in pulmonary arteries on autopsy examination • Correlation, albeit low (r=0.30), of medial thickness to preTx Transpulmonary gradient

  23. Medial hypertrophy

  24. Pathophysiological paradigm Moraes, et al. Circulation 2000;102:1718 - 1723

  25. Nitric oxide

  26. Impaired NO-dependent pulmonary vasodilatation if HF • Animal models • Ontkean et al, Circulation Research 1991;69:1088-1096 • Enhanced vasoconstriction and diminished vasodilatation in PA cf. TA of heart failure rat model compared to control Acetylcholine response

  27. Enhanced vasoconstriction in PA • Ontkean et al, Circulation Research 1991;69:1088-1096

  28. Human studies • Cooper et al, Am J Cardiol 1998;82:609–614 • 25 patients under went L&R catheterisation

  29. Methods • Doppler wire in left lower pulmonary artery • Sequential infusions into PA of • Phenylephrine at 10-7mol/L • L-NMMA at 3x10-5 and 6x10-5 mol/L • With 5% dextrose for 10 mins as interval wash out between each drug

  30. L-NMMA Blunted vaso-constriction Cooper et al, Am J Cardiol 1998;82:609–614

  31. Phenylephrine Cooper et al, Am J Cardiol 1998;82:609–614

  32. Regarding NO • Locally produced vaso-dilating factor • Blunted response to NO in CCF • Especially at raised PVR

  33. Endothelin-1 (ET1) • Vasoactive peptide first discovered in 1988 CsA, cyclosporin A; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IL-1, interleukin-1; LDL, low-density lipoprotein; VEGF, vascular endothelial growth factor. Remuzzi, Perico and Benigni, Nature Reviews Drug Discovery 1, 986-1001 (December 2002)

  34. Biological Actions of Endothelin

  35. Biological Actions of Endothelin

  36. ET1 • 2 receptor subtypes ETA and ETB • Ratio of A to B is 9:1 in pulmonary vasculature • ET1 cleared in the lungs • Clearance is mediated by ETB

  37. ET 1 clearance • ETB is down regulated in failing myocardium • Zolk at el, Circulation 1999; 99(16) 2118 -33 DCM n= 11 NF n= 9

  38. Raised ET1 levels in CCF CCF (n=20) vs. controls (n = 8) ET levels related to Heart rate PAP RAP PVR Not related to MAP SVR PCWP CI or SV Cody et al, Circulation 1992;85(2):504-509

  39. Big ET predicts mortality • 218 patient on HTx waiting list • Compared ET levels to survival Hulsman et al J Am Coll Cardiol 1998;32:1695–700

  40. As do other vaso-active peptides No relationship between VO2max and survival Hulsman et al J Am Coll Cardiol 1998;32:1695–700

  41. ET related to reduced exercise capacity • Krum et al, AJC 1995; 75(17):1284 – 86 • 12 male patients, mean EF 16% (8 -34%) • 10 control patients (9 men, 1 woman) • Bicycle ergometer, cardiopulmonary capacity

  42. However... • Are these factors (NO and ET1) mediators or markers? • Therapeutic interventions aimed at ET1 antagonism and NO augmentation have attempted to address this

  43. Inhaled NO at rest • Loh et al, Circulation 1994; 90(6): 2780 – 85 • 19 pts with class III-IV CCF 10 mins of NO at 80ppm

  44. Increased PCWP Loh et al, Circulation 1994; 90(6): 2780 – 85

  45. No change in CI Loh et al, Circulation 1994; 90(6): 2780 – 85

  46. NO during exercise testing • Koelling AJC 1998;81 (12): 1494 – 97 • 14 pts undergoing HTx evaluation (Class III-IV) • Bicycle CPX, radionuclear ventriculography, and cardiac catheterisation • Rest study as baseline • All repeated whilst breathing 40ppm NO. • Except cardiac catheterisation

  47. Koelling AJC 1998;81 (12): 1494 – 97

  48. Regarding NO augmentation • Most benefit in those with worse disease • Cumbersome to deliver inhaled NO

  49. Endothelin Receptor Antagonists • Demonstrated benefit in PAH • Promising evidence in animal studies of ischaemic HF • REACH – 1 – bosentan in CCF • Pilot study • ENABLE 1 and 2 bosentan in lower doses • EARTH – darusentan in CCF

  50. REACH – 1 – bosentan in CCF • Packer et al, Journal of Cardiac Failure Vol. 11 No. 1 2005 • Pilot, dose finding study • N= 370 pts with CCF • Placebo (N= 126) Vs Bosentan slow titration (N= 121) • Bosentan fast titration (N =123) • to a target dose of 500 mg twice daily

More Related